Format

Send to

Choose Destination
Nat Rev Drug Discov. 2011 Oct 21;10(11):835-52. doi: 10.1038/nrd3578.

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Author information

1
Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, BOX 1234, New York 10029, USA.

Erratum in

  • Nat Rev Drug Discov. 2011 Dec;10(12):963.

Abstract

The use of nanotechnology for medical purposes--nanomedicine--has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

PMID:
22015921
PMCID:
PMC3623275
DOI:
10.1038/nrd3578
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center